This trial (molecular characterization trial) focuses on rectal cancer, a common cancer that is treated with radiotherapy (RT) as standard of care and represents a setting in which to study the effects of RT on the immune system.
Histologically confirmed diagnosis of adenocarcinoma of the rectum
Age ≥ 18 years
ECOG performance status 0-1
cT2-T3N0 or cT1-3N1 or cT4 or cN2
Recurrent rectal cancer
Primary unresectable rectal cancer is defined as a primary rectal tumor which, on the basis of either physical exam or pelvic MRI, is deemed to be adherent or fixed to adjacent pelvic structures (en bloc resection will not be achieved with negative margins).
Patients who have received prior pelvic radiotherapy
Patients with prior allogenic stem cell or solid organ transplantation.
Weill Medical College of Cornell University
Lead sponsor
National Cancer Institute (NCI)
Collaborator